The production of TNF in all these processes has thus gained prominence in the development of biological agents directed towards IBD in both Crohn’s disease (CD) and ulcerative colitis (UC) to the extent that anti-TNF (i.e., infliximab, adalimumab, golimumab) are still among the biologics of first choice in the therapeutic management of IBD and related major extraintestinal manifestations [15,16,17]. The gene discussed is TNF; the disease is Crohn disease.